Movement Disorders

Pagan discussed unexpected findings from the InfusON study patient interviews that could influence how neurologists introduce CSAI therapy and how these insights, along with the latest data on MAO-B inhibitors, could shape future treatment combinations for Parkinson disease.

Here's some of what is coming soon to NeurologyLive® this week.

A physician assistant specializing in Parkinson disease talked about how emerging technologies and proactive care models could transform the treatment landscape for Parkinson disease. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 2, 2025.

In this segment, Pagan discussed the benefits of using AI in research and clinical practice, while also highlighting key considerations and cautions for clinicians.

In this segment, Pagan shared strategies to enhance patient adherence and comfort with long-term CSAI use, and offered his perspective on the evolving role of CSAI in managing complex motor fluctuations in Parkinson disease.

Moira Kapral, MD, MSc, reflects on her SEQUINS Hall of Fame recognition, the evolution of brain health equity, and her work addressing disparities in stroke care.

Robert J. Adams, MS, MD, reflects on his SEQUINS Hall of Fame recognition, his work on stroke prevention, and the importance of equity in brain health.

Barbara Vickrey, MD, MPH, discusses her SEQUINS Hall of Fame honor, the evolution of healthcare delivery models, and the role of mentorship in fostering equity in neurology.

Lewis B. Morgenstern, MD, reflects on his SEQUINS Hall of Fame recognition, the importance of health equity research, and his ongoing efforts to reduce stroke disparities.

Cheryl Bushnell, MD, MHS, a professor of neurology at Wake Forest University, discussed her SEQUINS Hall of Fame recognition, her work on sex differences in stroke risk, and her ongoing efforts to improve stroke care equity.

Explore the latest advancements in cell and gene therapies for Parkinson disease, featuring cutting-edge treatments and clinical trial updates from top innovators in the field.

The REGENERATE-PD trial is a phase 2 study assessing the safety and efficacy of the investigational gene therapy AB-1005 in patients with moderate-stage Parkinson disease.

The chief scientific officer of the Parkinson’s Foundation talked about how broad genetic testing through PD GENEration is uncovering valuable prognostic and diagnostic insights in Parkinson disease. [WATCH TIME: 4 minutes]

A new meta-analysis revealed that the efficacy of MRI-guided focused ultrasound decreased over time in essential tremor, with sensory symptoms and unsteadiness as common adverse effects.

Pooled analysis from KINECT-3 and KINECT-4 confirms valbenazine’s long-term safety and efficacy in managing tardive dyskinesia in elderly patients.

The ZEISS INTRABEAM 700 advances neurosurgical oncology by enabling precise intraoperative radiotherapy delivery, improved workflow efficiency, and enhanced collaboration between neurosurgeons and oncologists.

Pagan offered advice to early-career neurologists on how to stay current in the rapidly evolving field, emphasizing the importance of attending meetings and continuing education.

Panelists discuss how early recognition of dyskinesia symptoms, ongoing patient-clinician communication, and individualized treatment strategies are key to effectively managing Parkinson disease and improving patients’ quality of life.

Pagan talked about discussed pharmacokinetic-pharmacodynamic data supporting the use of amantadine ER for dyskinesia in Parkinson disease and compared the safety profiles of rasagiline and safinamide to guide add-on therapy decisions.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending April 26, 2025. [WATCH TIME: 3 minutes]

NLX-112 demonstrated safety and potential efficacy in reducing levodopa-induced dyskinesia and improving motor symptoms in Parkinson disease, with additional benefits seen in patients also receiving stable amantadine.

Roche has updated its phase 2 GENERATION HD2 trial to continue testing only the higher 100 mg dose of tominersen, following interim data favoring its potential clinical benefit in Huntington disease.

In this phase 2 trial, TTNS using the Geko device was safe and well tolerated but showed no significant benefit over sham in improving urinary symptoms in Parkinson disease.